期刊
JOURNAL OF NEURO-ONCOLOGY
卷 91, 期 1, 页码 47-50出版社
SPRINGER
DOI: 10.1007/s11060-008-9676-4
关键词
Advanced renal cell carcinoma; Sorafenib; Brain metastases
We report the case of a 75-year old woman who received sorafenib (Nexavar (R), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据